$HIMS Q2 Results - our take as healthcare venture capitalists
Tue Aug 05 2025
Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly.
We spend a lot of time discussing the legality of HIMS current FDA strategy and how/if HIMS can compete in a world with increasing competition from players like Function Health and Superpower.
This is not financial advice.
www.xeiavp.com
More
Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly. We spend a lot of time discussing the legality of HIMS current FDA strategy and how/if HIMS can compete in a world with increasing competition from players like Function Health and Superpower. This is not financial advice. www.xeiavp.com